Bob
Senior Member
- Messages
- 16,455
- Location
- England (south coast)
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10147357.htm
Extracts:
Extracts:
Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing facility in New Brunswick, NJ. During the tour, visitors were taken throughout the Alferon® and Ampligen® manufacturing suites and also via our Research and Development labs, where there has been a significant amount of resources spent on trying to find a biomarker for Ampligen® to treat Chronic Fatigue Syndrome (CFS).
Hemispherx Biopharma's President Thomas K. Equels said the Company has invested more than $1 million over the past year researching the relationship between natural killer (NK) cells and severe Chronic Fatigue Syndrome. Equels said Hemispherx is also in the process of evaluating the relationship between responders to its experimental therapeutic, Ampligenx(R), and NK cell levels in CFS victims. "We believe the results will help us to better understand the etiology of the disease, and most importantly, identify with a higher level of certainty those who will be Ampligenx(R) responders," said Equels. "Our search for a viable biomarker is an important component in moving Ampligenx(R), an experimental therapeutic, along the path to approval in the United States and in other countries." Accordingly, Equels said the Company maintained and improved its Ampligenx(R) production facilities in anticipation of success.
Thomas Equels, President of Hemispherx, stated; "We have invested over $1million over the past year researching the relationship between natural killer (NK) cells and severe CFS. We are also in the process of evaluating the relationship between responders to our experimental therapeutic, Ampligen®, and NK cell levels in CFS victims. We believe the results will help us to better understand the etiology of the disease, and most importantly, identify with a higher level of certainty those who will be Ampligen® responders. Our search for a viable biomarker is an important component in moving Ampligen®, an experimental therapeutic, along the path to approval here and in other countries. Accordingly, we have maintained and improved our Ampligen® production facilities in anticipation of success."